Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Current and future strategies in nonclear-cell metastatic renal cell carcinoma.

Current opinion in urology - 1 Sept 2015

Albiges Laurence, Escudier Bernard

Abstract excerpt

PURPOSE OF REVIEW: Therapeutic options for patients with metastatic nonclear-cell renal cell carcinoma (non-ccRCC) are limited and display minimum benefit. Conducting clinical trials in these rare and heterogeneous diseases without identified key biological drivers is a challenge for drug development. A growing body of prospective dedicated clinical trials and large molecular characterization initiatives are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Renal Cell
Share to Kidney Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Diagnostic Techniques

Share to Molecular Targeted Therapy

Share to Precision Medicine

Share to Predictive Value of Tests

Share to Proto-Oncogene Mas

Source

Identifiers

PMID: 26153638
DOI: 10.1097/MOU.0000000000000197

Genes

MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Current and future strategies in nonclear-cell metastatic renal cell carcinoma.PMID 26153638Read ↗

Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the LiteratureSemantic proximity Read ↗

Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategiesSemantic proximity Read ↗

Everolimus plus bevacizumab is an effective first-line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial.Semantic proximity Read ↗

Anti-Angiogenesis and Immunotherapy: Novel Paradigms to Envision Tailored Approaches in Renal Cell-CarcinomaSemantic proximity Read ↗

Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials.Semantic proximity Read ↗

Immune-Based and Novel Therapies in Variant Histology Renal Cell CarcinomasSemantic proximity Read ↗

Treatment strategies for clear cell renal cell carcinoma: Past, present and futureSemantic proximity Read ↗

Targeting miRNAs in renal cell carcinoma: emerging therapeutic strategiesSemantic proximity Read ↗

Kidney cancer pathology in the new context of targeted therapy.Semantic proximity Read ↗

Papillary renal cell carcinoma: A review of the current therapeutic landscape.Semantic proximity Read ↗

Current updates and future perspectives on the management of renal cell carcinoma.Semantic proximity Read ↗

Papillary renal cell carcinoma: current progress and future directions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.